Treatment News : Viread Approved for Children 2 and Up

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 20, 2012

Viread Approved for Children 2 and Up

Viread (tenofovir), Gilead Sciences’ nucleotide reverse transcriptase inhibitor, has been approved for children living with HIV, according to a U.S. Food and Drug Administration (FDA) announcement. To facilitate correct pediatric use of the drug, the agency also approved a powder formulation for children between the ages of 2 and 5 and low-dose tablets to meet pediatric dosing needs.

The FDA originally approved Viread in 2001 as a once-daily 300 milligram (mg) tablet for adults living with HIV. In March 2010, the 300 mg dose was approved for use in the United States among adolescents between the ages of 12 and 17.

The new pediatric approval is based on data from a Phase III safety and efficacy clinical trial of a Viread-containing antiretroviral regimen compared to an antiretroviral regimen containing Retrovir (zidovudine) or Zerit (stavudine) in children living with HIV between the ages of 2 and 12. The safety profile observed in the study was consistent with that observed in clinical trials in adults.

In addition to allowing the drug to be prescribed for pediatric HIV, the FDA approved three lower-strength once-daily tablets of Viread in doses of 150 mg, 200 mg and 250 mg for children who can swallow pills. The agency also approved an oral powder formulation of Viread for children between the ages of 2 and 5.

Search: Viread, tenofovir, children, dosing, pediatrics, powder


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    juliar33
    brooklyn
    New York


    jimmy807
    San Antonio
    Texas


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.